UNSPSC 51151649: Mepenzolate

This classification denotes an antimuscarinic agent with the molecular formula C21H26NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ONW3LB39P7, chemically known as 3-hydroxy-1, 1-dimethylpiperidinium bromide benzilate but generally known as mepenzolate, which bears US NIH Compound Identifier 4057. European Medicines Agency schedules Mepenzolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14513MIG.

UNSPSC 51151649 Mepenzolate is a Commodity code that nominally designates a specific pharmaceutical compound, but the recent state and local opportunities posted under it do not involve mepenzolate procurement; instead, they reflect naloxone, safe drug deactivation systems, and direct-to-manufacturer pharmacy benefit program design. The code shows a mismatch between its nominal scope and the work actually being solicited under it. Seminole County, Florida solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually via IFB 60459723LAS in June 2026, with deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, with no fixed budget or formal evaluation criteria at the exploratory stage.

The code generates minimal relevant recent activity. Geographic coverage extends to Florida and Texas, but the opportunities posted under this code do not align with mepenzolate procurement or pharmaceutical ingredients broadly — they track instead to opioid antagonists, drug disposal systems, and state pharmacy benefit program innovation. Business development professionals should verify whether this code is the appropriate taxonomy match for the actual goods or services under consideration, as the issuing bodies appear to have tagged unrelated procurement activity to this code. The Seminole County opportunity carried a fixed-fee, two-year term with one-year renewal option and required E-Verify compliance and standard insurance coverage; the Texas HHS RFI represents a pre-RFP market-intelligence phase with no award timeline or budget specified. Neither opportunity identifies specific set-aside designations.